Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Plus Bendamustine for Relapsed/Refractory Follicular Lymphoma
NCT04587687Phase 2Recruiting
- Sponsor
- University of California, Davis
- Start
- Dec 2020
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in follicular lymphoma (FL), sponsored by University of California, Davis. Primary endpoints: Complete Response Rate up to 2 years and Best Overall Response Rate up to 2 years. Started Dec 2020; status: recruiting.
02
Drugs
brentuximab vedotin
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04587687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04587687.